2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160844
    CT-133 2417155-47-4 98%
    CT-133 is a selective and potent CRTH2 Receptor antagonist, with a Ki value of 2.2 nM. The Ki value for the DP1 receptor is greater than 3800 nM. CT-133 inhibits neutrophil migration induced by PGD2 (HY-101988). CT-133 significantly alleviates lung inflammation and improves lung function impairment in a mouse model of acute lung injury (ALI) induced by cigarette smoke. CT-133 effectively inhibits the excessive expression of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and chemokines (KC), and reverses the inhibition of the anti-inflammatory factor IL-10. CT-133 can be used for the study of ALI.
    CT-133
  • HY-160980
    Sornidipine 95105-77-4 98%
    Sornidipine is a calcium channel blocker. Sornidipine also reduces neurogenic inflammation. Sornidipine reduces the inflow of calcium ions into cells by blocking L-type calcium channels, thereby reducing the contraction of vascular smooth muscle, leading to vasodilation and decreased blood pressure. Sornidipine can be used to study the cardiovascular system especially in hypertension and related cardiovascular diseases.
    Sornidipine
  • HY-160998
    YM-344031 671204-98-1 98%
    YM-344031 is an orally active antagonist for CCR3. YM-344031 inhibits binding of Eotaxin-1 and RANTES to CCR3, with IC50 of 3.0 and 16.3 nM. YM-344031 inhibits ligand-induced rise in intracellular Ca[2+] and the ligand-induced chemotaxis. YM-344031 inhibits eotaxin-1-induced changes in eosinophil morphology in macaques blood, and prevents allergic skin reactions in a mouse allergy model.
    YM-344031
  • HY-161004
    AMOZ-CH-acid 1416047-56-7 98%
    AMOZ-CH-acid (Hapten 5) is an immunizing and heterologous hapten. AMOZ-CH-acid and ovalbumin conjugate is a coating antigen that improves assay sensitivity.
    AMOZ-CH-acid
  • HY-161006
    TETS-C4-acid 98%
    TETS-C4-acid (Compound 2d) is a hapten coupled directly to a carrier protein through a carboxylic acid functionality. TETS-C4-acid (Compound 2d) can be used to detect tetramethylenedisulfotetramine (TETS).
    TETS-C4-acid
  • HY-161019
    JAK1/TYK2-IN-4 2734918-33-1 98%
    JAK1/TYK2-IN-4 is a dual inhibitor of JAK and TYK2, with IC50s of 39 nM and 21 nM, respectively. JAK1/TYK2-IN-4 has oral bioavailability.
    JAK1/TYK2-IN-4
  • HY-161026
    JM-9 2901052-78-4 98%
    JM-9 is a inhibitor of MD2. JM-9 suppresses high glucose and palmitic acid -induced inflammation in MPMs. JM-9 improves diabetic kidney disease by inhibiting MD2-mediated inflammation.
    JM-9
  • HY-161032
    IP6K2-IN-1 2926679-10-7 99.47%
    IP6K2-IN-1 is a selective flavonoid-based IP6K2 inhibitor with an IC50 value of 0.55 μM. IP6K2-IN-1 shows higher inhibitory potency against IP6K2 than IP6K1 and IP6K3. IP6K2-IN-1 can be utilised as a hit compound for further structural modifications of IP6K2 inhibitors.
    IP6K2-IN-1
  • HY-161072
    CSC-6 354559-44-7 98%
    CSC-6 is a NLRP3 inhibitor. CSC-6 can significantly inhibit IL-1β secreted by PMATHP-1 cells with an IC50 value of 2.3 μM. CSC-6 specifically binds NLRP3 and inhibits NLRP3 activation by blocking ASC oligomerization during NLRP3 assembly. CSC-6 effectively reduces the symptoms of NLRP3 overactivation-mediated sepsis and gout in mouse models.
    CSC-6
  • HY-161107
    OX04529 3028055-50-4 98%
    OX04529 (compound 69) is a potent, selective and orally active agonist of GPR84. OX04529 inhibits FSK-induced cAMP production with an EC50 of 0.0185 nM. OX04529 displayed excellent potency, high G-protein signaling bias.
    OX04529
  • HY-161120
    NLRP3-IN-27 2997864-57-8 98%
    NLRP3-IN-27 is a selective NLRP3 inhibitor with a IC50 value of 0.55 μM. NLRP3-IN-27 can be used in the study of inflammation and immunity.
    NLRP3-IN-27
  • HY-161131
    Lenalidomide 4'-alkyl-C3-azide 2399455-71-9 98%
    Lenalidomide 4'-alkyl-C3-azide (compound 4a) is a click chemical modified Lenalidomide (HY-A0003) that can be used to synthesize PROTACs. Lenalidomide is an orally active immunomodulator and a ligand for the ubiquitin E3 ligase cereblon (CRBN). Lenalidomide 4'-alkyl-C3-azide contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition reactions (SPAAC) can also occur with molecules containing DBCO or BCN groups.
    Lenalidomide 4'-alkyl-C3-azide
  • HY-161139
    JAK1-IN-14 98%
    JAK1-IN-14 (Compound 12a) is a potent and selective JAK1 inhibitor. JAK1-IN-14 inhibits JAK1 and JAK2 with an IC50 value of 12.6 nM and 135 nM. JAK1-IN-14 suppresses hepatic fibrosis levels and can be used for the research of liver fibrosis and inflammatory diseases.
    JAK1-IN-14
  • HY-161147
    COX-2-IN-37 98%
    COX-2-IN-37 (compound 11) is a potent and selective COX-2 inhibitor. COX-2-IN-37 has strong antioxidant activity with an IC50 of 33.0 μg/mL.
    COX-2-IN-37
  • HY-161155
    HDAC6-IN-31 98%
    HDAC6-IN-31 (compound 8m) is a selective HDAC6 inhibitor, with the IC50 value of 0.026 μM, that significantly inhibits the production and release of pro-inflammatory cytokines. While HDAC6 is critically involved in the activation of inflammasomes, HDAC6-IN-31 has the potential to inhibit NLRP3 inflammasome-driven inflammatory diseases. HDAC6-IN-31 also inhibits glioblastoma cell migration.
    HDAC6-IN-31
  • HY-161240
    MAO-B-IN-30 82973-15-7 98.53%
    MAO-B-IN-30 (compound IS7) is a potent, selective and cross the blood-brain barrier MAO-B inhibitor with IC50 values of 19.176, 0.082 µM for MAO-A and MAO-B, respectively. MAO-B-IN-30 shows antiproliferative activity and non-cytotoxic. MAO-B-IN-30 reduces TNF-alpha, IL-6, NF-kB levels. MAO-B-IN-30 has the potential for the research of Parkinson's disease.
    MAO-B-IN-30
  • HY-161249
    Vanin-1-IN-4 2173134-02-4 98%
    Vanin-1-IN-4 (compound (S)-1) is vanin-1 inhibitor with a chiral methyl substituent, with profils as potent drug-candidate but exist as an amorphous solid.
    Vanin-1-IN-4
  • HY-161255
    3,4-DAA 2117759-07-4 98%
    3,4-DAA is an orally active Anthranilic acid derivative with potent immunosuppressive activities. 3, 4-DAA can alleviate the severity of colitis through inhibiting Th1 cells response, promoting Th2 cytokines expression and inducing CD4+CD25+ T cells expression. 3,4-DAA suppressed expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) release from EOC20 cells induced by IFN-γ and Lipopolysaccharide.
    3,4-DAA
  • HY-161259
    JAK-IN-36 98%
    JAK-IN-36 (Compound 12e) is a potent and selective inhibitor of Janus Kinase 1 (JAK1) with a IC50 value of 2.2 nM. JAK-IN-36 can be used in the study of autoimmune diseases.
    JAK-IN-36
  • HY-161266
    COX-2/NLRP3-IN-1 3057274-61-7 98%
    COX-2/NLRP3-IN-1 (Compound 6k) is a COX-2/NLRP3 inhibitor with a IC50 of 1.53 μM for COX-2. COX-2/NLRP3-IN-1 exerts anti-inflammatory effects by inhibiting the NF-κB/NLRP3 signaling pathway.
    COX-2/NLRP3-IN-1
Cat. No. Product Name / Synonyms Application Reactivity